MétaCan
Menu
Back to cohort

Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC).

2011· article· en· W2039457659 on OpenAlexaffabout
Bernhard J. Eigl, Scott North, Nevin Murray, Daniel YC Heng, Eric Winquist, Jean Powers, Wendy Walsh, Elizabeth A. Eisenhauer, Jeremy A. Squire, Michael Cox, Kim N.

Bibliographic record

VenueMolecular Cancer Therapeutics · 2011
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsVancouver General HospitalOntario Institute for Cancer ResearchBC Cancer Agency
Fundersnot available
KeywordsMedicineProstate cancerInternal medicineClinical endpointOncologyCancerAdverse effectAndrogen deprivation therapyLymph nodeProstateClinical trial

Abstract

fetched live from OpenAlex

Abstract Background: SB939 is a potent oral inhibitor of class I, II and IV histone deacetylases (HDACs) with high tumor tissue selectivity. These 3 classes of HDAC are highly expressed in prostate cancer and associated with poor clinical outcomes. HDAC inhibition has been shown to abrogate androgen receptor signaling via inactivation of HSP90, and may have relevance particularly in TMPRSS2-ERG fusion positive prostate cancer. Methods: In this multicenter phase II study, pts with CRPC received SB939 60mg every other day 3 times per week × 3 weeks on a 28-day cycle. Primary endpoints were PSA response rate (RR) (>50% decline from baseline for > 4 weeks) and progression free survival (PFS). Secondary endpoints included objective response rate; response duration, overall survival; circulating tumor cell (CTC) enumeration at baseline, 6 and 12 weeks; TMPRSS2-ERG fusion analysis; correlative analysis of archival tissue; and safety. Planned sample size was 29 pts, the hypotheses (PSA RR <2% vs. ≥15%) could be tested at 10% and levels. Results: Twenty-nine pts have been accrued. Median age is 69, 25 pts had received no prior chemotherapy, ECOG performance status was 0/1 in 48%/52% of pts. Bone/lymph node/visceral metastases were present in 86%/69%/10% of pts. The median number of cycles of SB939 administered is 2 (range 1–6) with 7 pts still continuing treatment. Adverse events were generally grade 1–2, with 5 patients experiencing grade 3 events (fatigue (5 pts), vomiting (1 pt) and dyspnea (1pt)). To date, a confirmed PSA response has been noted in 2 pts (7%). In 8 RECIST-evaluable pts, there were no objective responses, and 3 pts had stable disease lasting from 3.4 to 5.6 months. CTC favorable conversion (from ≥5 at baseline to <5 at 6 or 12 weeks) was observed in 9/14 evaluable patients (64%) and unfavorable CTC levels (>5) at 6 weeks correlated with PSA progression. RT-PCR for presence of TMPRSS2-ERG transcripts from whole blood and FISH analyzes of CTC and archival tissue for TMPRSS2-ERG fusion and PTEN deletion status are ongoing. Conclusion: SB939 is well tolerated and has shown early evidence of activity in CRPC. Analysis of more mature data will be required to determine whether this agent warrants further study, and whether TMPRSS2-ERG status might predict for response to SB939. Supported by grants from the Canadian Cancer Society and the Ontario Institute for Cancer Research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A221.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.395
Threshold uncertainty score0.686

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.089
GPT teacher head0.377
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2011
Admission routes2
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicProstate Cancer Treatment and ResearchFrench-language works237,207